Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV).

Lin CT, Tang HY, Han YS, Liu HP, Huang SF, Chien CH, Shyy J, Chiu JJ, Chen X.

Int J Biomed Sci. 2010 Dec;6(4):301-9.

2.

Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity.

Jacotot E, Callebaut C, Blanco J, Krust B, Neubert K, Barth A, Hovanessian AG.

Eur J Biochem. 1996 Jul 15;239(2):248-58.

3.

Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.

Liu X, Harada N, Yamane S, Kitajima L, Uchida S, Hamasaki A, Mukai E, Toyoda K, Yamada C, Yamada Y, Seino Y, Inagaki N.

Life Sci. 2009 Jun 19;84(25-26):876-81. doi: 10.1016/j.lfs.2009.03.022. Epub 2009 Apr 7.

PMID:
19358859
4.

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

Marchetti C, Di Carlo A, Facchiano F, Senatore C, De Cristofaro R, Luzi A, Federici M, Romani M, Napolitano M, Capogrossi MC, Germani A.

Diabetologia. 2012 Jan;55(1):236-44. doi: 10.1007/s00125-011-2213-6. Epub 2011 Jun 8.

PMID:
21656024
5.
6.

Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.

Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.

Clin Lung Cancer. 2012 Sep;13(5):385-90. doi: 10.1016/j.cllc.2011.11.009. Epub 2012 Jan 28.

PMID:
22285568
7.

RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.

Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.

Eur J Pharmacol. 2011 Feb 10;652(1-3):157-63. doi: 10.1016/j.ejphar.2010.06.001. Epub 2010 Jun 9. Erratum in: Eur J Pharmacol. 2011 Mar 25;655(1-3):121. multiple author names added.

PMID:
20540938
8.
9.

In silico approaches to predict the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) inhibitors.

Nongonierma AB, Mooney C, Shields DC, FitzGerald RJ.

Peptides. 2014 Jul;57:43-51. doi: 10.1016/j.peptides.2014.04.018. Epub 2014 May 2.

PMID:
24793774
10.
11.

Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.

Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M.

Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):209-17. doi: 10.1007/s00210-008-0277-8. Epub 2008 Apr 9.

PMID:
18398600
12.

Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs.

Faidley TD, Leiting B, Pryor KD, Lyons K, Hickey GJ, Thompson DR.

Exp Biol Med (Maywood). 2006 Sep;231(8):1373-8.

PMID:
16946406
13.

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.

Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS.

J Pharmacol Exp Ther. 2012 Feb;340(2):248-55. doi: 10.1124/jpet.111.186866. Epub 2011 Oct 24.

14.

Dipeptidyl-peptidase IV-beta--further characterization and comparison to dipeptidyl-peptidase IV activity of CD26.

Blanco J, Nguyen C, Callebaut C, Jacotot E, Krust B, Mazaleyrat JP, Wakselman M, Hovanessian AG.

Eur J Biochem. 1998 Sep 1;256(2):369-78.

15.
16.
17.

DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys.

Zhang Y, Chen Y, Cheng J, Guo Z, Lu Y, Tian B.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):139-44. doi: 10.1016/j.bbrc.2014.11.048. Epub 2014 Nov 21.

PMID:
25446112
18.

The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases.

Augustyns K, Van der Veken P, Senten K, Haemers A.

Curr Med Chem. 2005;12(8):971-98. Review.

PMID:
15853709
20.

Supplemental Content

Support Center